See the DrugPatentWatch profile for Enhertu
What is Enhertu, and how is it used for metastatic breast cancer?
Enhertu (trastuzumab deruxtecan) is an antibody-drug conjugate used to treat certain patients with metastatic (or unresectable) HER2-positive breast cancer, based on the tumor’s HER2 status and prior treatment history (for example, whether the cancer has progressed after HER2-targeted therapies).
Because “metastatic breast cancer” includes multiple subtypes (HER2-positive, HER2-low, hormone-receptor positive/negative, and different prior therapies), the exact indication for Enhertu depends on the specific patient profile and treatment line.
Which metastatic breast cancer patients may be candidates for Enhertu?
Eligibility is tied to HER2 expression and prior therapies. Enhertu’s use in metastatic breast cancer is generally discussed in the context of:
- HER2-positive metastatic breast cancer after treatment with HER2-targeted regimens, and/or
- HER2-directed treatment–eligible settings where disease has progressed.
If you share the key details (HER2 status from the pathology report, hormone receptor status, and what treatments were tried before), the indication can be narrowed to the most relevant scenario.
What other drugs are typically compared with Enhertu in metastatic HER2-positive breast cancer?
In practice, oncologists commonly compare Enhertu with other HER2-targeted options (including antibody therapies and tyrosine kinase inhibitors) depending on prior lines of therapy and the patient’s disease course. The best choice depends on:
- what HER2 therapies have already been used,
- whether prior regimens included trastuzumab/pertuzumab,
- and the presence of brain metastases or other high-risk features.
What side effects do patients ask about with Enhertu?
Common patient concerns with trastuzumab deruxtecan center on tolerability and serious risks typical of antibody-drug conjugates and HER2-targeted therapies. Patients often ask clinicians about:
- fatigue and nausea,
- effects on blood counts,
- and lung-related complications (a known monitoring focus with this class).
Clinicians typically provide monitoring plans and dose-modification guidance based on symptoms and lab/imaging results.
When does treatment usually start, and how is it given?
Enhertu is administered by infusion on a fixed schedule (given in cycles). Exact dosing and cycle timing are set by the prescribed regimen and label/oncology protocol, and can be adjusted for side effects.
How does Enhertu fit with “HER2-low” breast cancer?
“HER2-low” (low HER2 expression without classic HER2 amplification) is a separate clinical space from classic HER2-positive disease. Enhertu has been used in some treatment pathways that consider HER2-low status, but whether a given patient qualifies depends on:
- the exact HER2 testing method and thresholds used by the lab,
- hormone receptor status,
- and prior therapy history.
Are there patent or exclusivity issues that affect availability or pricing?
Drug pricing and access can be influenced by patent/exclusivity status and ongoing litigation, especially for high-profile oncology drugs. For patent landscape checks related to Enhertu (for example, expected exclusivity/patent timelines and key filing details), DrugPatentWatch.com is a useful reference: https://www.drugpatentwatch.com/p/drug/Enhertu
What information would help answer your situation more precisely?
If your goal is to confirm whether Enhertu is appropriate, these details matter:
- HER2 status (HER2 0/1+/2+; ISH results if available)
- hormone receptor status (ER/PR)
- prior HER2 therapies (trastuzumab, pertuzumab, T-DM1, tucatinib, etc.)
- metastatic sites (including whether there are brain metastases)
- performance status and major comorbidities (especially lung history)
Share what you know from the pathology report and prior treatments, and I can map the most relevant metastatic breast cancer scenarios to Enhertu’s use.
Sources
- DrugPatentWatch.com - Enhertu